Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China

8 oktober 2019 uppdaterad av: China National Center for Cardiovascular Diseases
This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI. This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and team building will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Cardiovascular disease (CVD) is a major concern in public health globally, as well as in China, and remarkable variations of resources available and health system performance have been noted. Acute myocardial infarction is one of the leading causes of mortality and morbidity, both in rural and urban area.

This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI.

This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Demographic characteristics, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be obtained and then, the treatment pattern and outcomes will be evaluated. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and professional training will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

New knowledge will be generated about STEMI management in China, to improve STEMI patients prognosis in future.

Studietyp

Observationell

Inskrivning (Förväntat)

200000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

  • Kina
    • Beijing
      • Beijing, Beijing, Kina, 100037
        • Rekrytering
        • Hongjian Wang
        • Kontakt:
        • Kontakt:
          • Yin Dong
          • Telefonnummer: 13552582795

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset

Beskrivning

Inclusion Criteria:

  • Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset.

Exclusion Criteria:

  • None

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Endast fall
  • Tidsperspektiv: Retrospektiv

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
All hospitals

All hospitals will take the treatment quality improvement strategies and tools into implementation.

Intervention: Behavioral: Quality improvement strategies and tools
Beteende: Quality improvement strategies and tools
Quality improvement strategies and tools

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Aspirin at arrival
Tidsram: 24 hours after admission
Proportion of aspirin use within 24 hours of admission among eligible patients
24 hours after admission
Clopidogrel (or ticagrelor) at arrival
Tidsram: 24 hours after admission
Proportion of Clopidogrel (or ticagrelor) use within 24 hours of admission among eligible patients
24 hours after admission
β-blockers at arrival
Tidsram: 24 hours after admission
Proportion of β-blockers use within 24 hours of admission among eligible patients
24 hours after admission
ECG at arrival
Tidsram: 24 hours after admission
Proportion of ECG test within 10 minutes of admission among eligible patients
24 hours after admission
Reperfusionsterapihastighet
Tidsram: 24 timmar efter intagningen
Reperfusionsterapihastighet definieras som utnyttjandegrad av trombolytisk terapi eller primär PCI-behandling bland patienter indikerade med reperfusionsterapi.
24 timmar efter intagningen
Time delay from failure of fibrinolysis to angiography(The time from start of fibrinolysis to evaluation of its efficacy is 60-90min)
Tidsram: 10 days on average (during hospitalization)
The proportion of failure of fibrinolysis to balloon within 90 minutes among all patients receiving PCI.
10 days on average (during hospitalization)
Time delay from start of fibrinolysis to angiography(if fibrinolysis is successful)
Tidsram: 10 days on average (during hospitalization)
The proportion of from fibrinolysis to balloon (if fibrinolysis is successful) within 2-24hours among all patients receiving PCI.
10 days on average (during hospitalization)
Aktuell trombolytisk terapi
Tidsram: 24 timmar efter intagningen
Andelen dörr till nål-tid (D2N) inom 30 minuter bland alla patienter som får fibrinolytisk behandling.
24 timmar efter intagningen
Timeliness of primary PCI
Tidsram: 24 hours after admission
The proportion of door to balloon (D2B) within 90 minutes among all patients receiving primary PCI.
24 hours after admission
Door-in-Door-Out Time
Tidsram: 24 hours after admission
Percentage of patients whose median time from the emergency department arrival at STEMI referral facility to emergency department discharge from STEMI referral facility is equal or less than 30 min. discharge from STEMI referral facility is 30 min.
24 hours after admission
Time to Primary PCI Among Transferred Patients
Tidsram: 24 hours after admission
Percentage of patients whose median time from first medical contact (at or before emergency department arrival to the STEMI referral facility [e.g., non-PCI-capable facility]) to primary PCI at the STEMI receiving facility (PCI-capable facility) is equal or less than 120 min
24 hours after admission
Evaluation of LDL-C
Tidsram: 10 days on average (during hospitalization)
Percentage of patients with documentation in the hospital record that LDL-C is evaluated during hospitalization
10 days on average (during hospitalization)
Evaluation of left ventricular ejection fraction
Tidsram: 10 days on average (during hospitalization)
Percentage of patients with documentation in the hospital record that left ventricular ejection fraction is evaluated during hospitalization
10 days on average (during hospitalization)
Aspirin use during hospitalization
Tidsram: 10 days on average (during hospitalization)
Proportion of Aspirin use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Clopidogrel (or ticagrelor) use during hospitalization
Tidsram: 10 days on average (during hospitalization)
Proportion of Clopidogrel (or ticagrelor) use during hospitalization among eligible patients.
10 days on average (during hospitalization)
β-blockerare används under sjukhusvistelse
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel β-blockerare som används under sjukhusvistelse bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization
Tidsram: 10 days on average (during hospitalization)
Proportion of Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Statiner används under sjukhusvistelse
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel statiner som används under sjukhusvistelse bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
Aspirinanvändning vid utskrivning
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel acetylsalicylsyraanvändning vid utskrivning bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
Clopidogrel (eller ticagrelor) används vid utskrivning
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel användning av Clopidogrel (eller ticagrelor) vid utskrivning bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
β-blockerare används vid utskrivning
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel β-blockerare som används vid utskrivning bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge
Tidsram: 10 days on average (during hospitalization)
Proportion of angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge among eligible patients.
10 days on average (during hospitalization)
Statiner används vid utskrivning
Tidsram: 10 dagar i genomsnitt (under sjukhusvistelse)
Andel statiner som används vid utskrivning bland berättigade patienter.
10 dagar i genomsnitt (under sjukhusvistelse)
Aldosterone Antagonist at Discharge
Tidsram: 10 days on average (during hospitalization)
Proportion of Aldosterone Antagonist use at discharge among eligible patients.
10 days on average (during hospitalization)
Smoking cessation advice/ counseling at Discharge
Tidsram: 10 days on average (during hospitalization)
Proportion of patients received smoking cessation advice/ counseling
10 days on average (during hospitalization)
all-cause mortality during hospitalization
Tidsram: 10 days on average (during hospitalization)
Proportion of patients who were all-cause death during hospitalization
10 days on average (during hospitalization)
Cardiac mortality during hospitalization
Tidsram: 10 days on average (during hospitalization)
Proportion of patients who were cardiac death during hospitalization
10 days on average (during hospitalization)
30-day all-cause mortality
Tidsram: From admission to 30days
Proportion of patients who were all-cause death from admission to 30days
From admission to 30days
30-day cardiac mortality
Tidsram: From admission to 30days
Proportion of patients who were cardiac death from admission to 30days
From admission to 30days
30-day readmission rates
Tidsram: From hospital discharge to 30 days
Proportion of patients readmission from hospital discharge to 30days
From hospital discharge to 30 days
Cost during hospitalization
Tidsram: 10 days on average (during hospitalization)
Cost during hospitalization
10 days on average (during hospitalization)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

China National Center for Cardiovascular Diseases

Utredare

  • Huvudutredare: Zhe Zheng, Fuwai Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 juli 2018

Primärt slutförande (Förväntat)

31 december 2035

Avslutad studie (Förväntat)

31 december 2035

Studieregistreringsdatum

Först inskickad

9 september 2019

Först inskickad som uppfyllde QC-kriterierna

12 september 2019

Första postat (Faktisk)

13 september 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 oktober 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 oktober 2019

Senast verifierad

1 september 2019

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • NCCQI-CAD

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på ST Elevation hjärtinfarkt

Kliniska prövningar på Quality improvement strategies and tools

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Russia

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera